- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04384653
Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure
An Open-label, Single-dose, Randomized, Two-way, Two-period Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Subjects With Chronic Heart Failure
The proposed study aims to compare the pharmacokinetics and bioavailability of intravenous and subcutaneous Furosemide. Although these regimens are not intended to be bioequivalent, they are both expected to achieve therapeutic plasma levels and induce effective diuresis.
The test formulation in this study is a buffered solution, Furosemide Injection Solution at 30 mg/mL at pH 7.4 (range 7.0 to 7.8) and is intended for SC injection according to the instructions in the protocol. A commercial formulation of Furosemide Injection, USP will serve as the reference drug in this study, which will be administered by IV bolus. It contains furosemide 10 mg/mL in solution at alkaline pH of 8.0 to 9.3 and is marketed for IV and IM injection.
The primary objective of the study is to estimate the absolute bioavailability of furosemide administered by subcutaneous infusion compared with an equivalent dose of furosemide administered by IV bolus administration.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
DeLand, Florida, United States, 32720
- Accel Research Sites - DeLand Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- An Institutional Review Board (IRB)-approved informed consent is signed and dated prior to any study-related activities.
- Male and female subjects ≥18 and ≤ 80 years of age, with body weight <130 kg and body mass index (BMI) <38 kg/m2.
- Females will be non-pregnant, non-lactating, or post-menopausal, or surgically sterile (e.g., tubal ligation, hysterectomy),
- Females of childbearing potential will use TWO of the following forms of contraception: intrauterine device (IUD), IUD with spermicide, female condom with spermicide, contraceptive sponge with spermicide, an intravaginal system, diaphragm with spermicide, cervical cap with spermicide, a male sexual partner who agrees to use a male condom with spermicide, a sterile sexual partner.
- History of at least 3 months treated heart failure (NYHA class II/III) with presence of symptoms of chronic volume overload requiring ongoing treatment with oral furosemide at a dose of ≥40 mg per day for at least 30 days prior to Day -1.
- Agrees to abstain from using alcohol, caffeine-containing products, and tobacco-/nicotine-containing products while in residence at the CRU.
- Able to participate in the study in the opinion of the Investigator.
- Has the ability to understand the requirements of the study and is willing to comply with all study procedures.
Exclusion Criteria:
- Acute Decompensated Heart Failure (ADHF) or recent history of hospitalization for heart failure in the last 4 weeks.
- Worsening of signs or symptoms of heart failure in the two weeks prior to the Screening, or those expected to require IV loop diuretics or inpatient treatment for heart failure during the study.
- Systolic blood pressure (SBP) <90 mmHg.
- Temperature ≥38°C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment.
- Serum sodium <130 mEq/L and serum potassium <3.5 mEq/L.
- Significant other cardiac abnormalities which may interfere with study participation or study assessments.
- Current or planned treatment during the study with any IV therapies, including inotropic agents, vasopressors, levosimendan, nesiritide or analogues; or mechanical support (intraaortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device).
- Subject is cachectic.
- Diagnosed with Type I diabetes mellitus or Type II diabetes requiring insulin therapy.
- Presence or need for urinary catheterization, urinary tract abnormality, or disorder interfering with urination.
- Impaired renal function, defined as an estimated glomerular filtration rate (eGFR) on admission <45 mL/min/1.73m2, calculated using the simplified Modification of Diet in Renal Disease (sMDRD) equation.
- Indication of moderate-to-severe hepatic dysfunctions as determined by the Investigator.
- Administration of IV radiographic contrast agent within 72 hours prior to Screening or acute contrast-induced nephropathy at the time of Screening.
- Major surgery within 30 days prior to Screening.
- Administration of an investigational drug or implantation of investigational device, or participation in another interventional trial, within 30 days prior to Screening.
- Any surgical or medical condition, which in the opinion of the Investigator may pose an undue risk to the subject, interfere with participation in the study, or which may affect the integrity of the study data.
- Positive test for hepatitis B (HBsAg), hepatitis C (HCV), or human immunodeficiency virus (HIV) at Screening.
- Any positive urine drug screen at Screening or clinic admission.
- Concomitant use of any drugs known to interact with furosemide.
- History of alcohol abuse within 6 months prior to Screening and/or signs or symptoms of alcoholism, as determined by the Investigator.
- Any positive alcohol test on admission to the CRU.
- History of severe allergic or hypersensitivity reactions to furosemide.
- Donation of greater than 100 mL of either whole blood or plasma within 30 days prior to study drug administration.
- Been informed of possible COVID-19 exposure in past 4 weeks, or recent onset of signs or symptoms of possible COVID-19 infection, including cough, shortness of breath, or temperature ≥ 38°C .
- Traveled via airplane or cruiseship within the last 14 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment A
Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 1 and IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 2
|
Furosemide Injection Solution for subcutaneous administration (80 mg)
Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
Furosemide Injection Solution for subcutaneous administration (80 mg)
|
EXPERIMENTAL: Treatment B
IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 1 and Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 2
|
Furosemide Injection Solution for subcutaneous administration (80 mg)
Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
Furosemide Injection Solution for subcutaneous administration (80 mg)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioavailability
Time Frame: 0 to 24 hours
|
Relative absolute bioavailability following 5-hour subcutaneous infusion based on a comparison of AUC (subcutaneous: IV) of furosemide
|
0 to 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameters
Time Frame: 0 to 24 hours
|
PK parameters over the timeframe of 24 hours, including, but not limited to, maximum plasma concentration (Cmax), and time to Cmax (Tmax).
|
0 to 24 hours
|
Pharmacokinetic parameters
Time Frame: 0 to 24 hours
|
PK parameters over the timeframe of 24 hours, including, but not limited to, area under the concentration versus time curve (AUC) from time 0 (pre-dose) to 24 hours post-dose (AUC0-24), AUC from time 0 to the last measurable plasma concentration (AUClast) and to infinity (AUCinf), half-life (tó), apparent systemic clearance and volume of distribution (subcutaneous only), and systemic clearance and volume of distribution (IV only).
|
0 to 24 hours
|
Urine volume
Time Frame: 0 to 24 hours
|
Urine volume collected over 8 hours and 24 hours post-dose.
|
0 to 24 hours
|
Sodium concentration in urine
Time Frame: 0 to 24 hours
|
Sodium concentration in urine collected over 8 hours and 24 hours post-dose.
|
0 to 24 hours
|
Pain and discomfort
Time Frame: 0 to 5 hours
|
Infusion site pain/discomfort (IV and subcutaneous administration) measured using patient reported scales.
|
0 to 5 hours
|
Pain and discomfort
Time Frame: 0 to 5 hours
|
Infusion site pain/discomfort (IV and subcutaneous administration) measured using presence of erythema and edema both recorded through photography and assessed by Principal Investigator (PI)/designee-reported scales.
|
0 to 5 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bruce G Rankin, DO, CPI, FACOFP, Accel Research Sites - DeLand Clinical Research Unit
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SQI-01-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on Furosemide Injection Solution for subcutaneous administration (80 mg)
-
scPharmaceuticals, Inc.Completed
-
scPharmaceuticals, Inc.Completed
-
Geisinger ClinicTerminatedObesity | Diabetic Kidney Disease | Type 2 Diabetes Mellitus in Obese | CKD | Severe ObesityUnited States
-
University of AlbertaOctapharmaRecruitingPrimary Immune Deficiency Disorder | Secondary Immune DeficiencyCanada
-
Almirall, S.A.Completed
-
Fundación Instituto de Estudios de Ciencias de...Instituto de Investigación Biomédica de SalamancaCompletedLaparoscopic CholecystectomySpain
-
Biomedica Foscama S.p.A. Industria Chimico-FarmaceuticaNot yet recruiting
-
Vista KlinikNovartisTerminatedNeovascular Age-related Macular DegenerationSwitzerland
-
Leonardo ClavijoAmgenUnknownPeripheral Arterial DiseaseUnited States
-
Neupharma SrlSintesi Research Srl; Pari Pharma GmbH; AptuitCompleted